Showing 1 - 6 of 6
We build a model of firm-level innovation, productivity growth and reallocation featuring endogenous entry and exit. A …
Persistent link: https://www.econbiz.de/10010655943
comparisons of innovations to incumbent technologies. For each innovation in our dataset, we observe its price and quality, as … well as the price and quality of an incumbent technology treating the same disease. Our main finding is that an innovation … over time. We calibrate that price declines of 4% between the time when a treatment is a new innovation and the time when …
Persistent link: https://www.econbiz.de/10012977187
Using detailed edit-level data over eight years across a large number of articles on Wikipedia, we find evidence for a positive spillover effect in editing activity. Cumulative past contributions, embodied by the current article length, lead to significantly more editing activity, while...
Persistent link: https://www.econbiz.de/10010780794
government risk facing investors in medical innovation. This risk slows down medical innovation because investors must be … argument is that, by allowing better risk sharing between those investing in medical innovation and capital markets more … generally, FDA hedges could ultimately spur medical innovation and improve the health of patients …
Persistent link: https://www.econbiz.de/10012959215
This paper develops a framework to analyze the relationship between the diffusion of new technologies and the decentralization decisions of firms. Centralized control relies on the information of the principal, which we equate with publicly available information. Decentralized control, on the...
Persistent link: https://www.econbiz.de/10005151064
We build a model of firm-level innovation, productivity growth and reallocation featuring endogenous entry and exit. A …
Persistent link: https://www.econbiz.de/10012900520